Syndax Pharmaceuticals Stock Cash Per Share

SNDX Stock

USD 16.09 0.49 3.14%

Syndax Pharmaceuticals fundamentals help investors to digest information that contributes to Syndax Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Syndax Stock. The fundamental analysis module provides a way to measure Syndax Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Syndax Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	Cash Per Share	8.21	8.62

Cash Per Share is likely to rise to 8.62 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Syndax Pharmaceuticals Company Cash Per Share Analysis

Syndax Pharmaceuticals' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Cash Per Share

Total Cash

Average Shares

More About Cash Per Share | All Equity Analysis

Current Syndax Pharmaceuticals Cash Per Share

5.82 X

Most of Syndax Pharmaceuticals' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Syndax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Syndax Cash Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Syndax Pharmaceuticals is extremely important. It helps to project a fair market value of Syndax Stock properly, considering its historical fundamentals such as Cash Per Share. Since Syndax Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Syndax Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Syndax Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Long Term Debt	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Property Plant Equipment	Capital Surpluse	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock	Long Term Debt Total
Total Assets		1.0	0.9	-0.93	-0.93	0.88	0.94	0.63	1.0	-0.64	0.98	0.96	0.59	0.6	0.73	0.61	0.78	0.88	0.9	0.72	0.9	0.94	0.89
Total Stockholder Equity	1.0		0.9	-0.93	-0.92	0.87	0.95	0.6	1.0	-0.65	0.98	0.95	0.58	0.62	0.72	0.6	0.78	0.88	0.91	0.71	0.9	0.94	0.89
Current Deferred Revenue	0.9	0.9		-0.82	-0.81	0.82	0.86	0.44	0.89	-0.47	0.88	0.82	0.4	0.68	0.52	0.37	0.84	0.72	0.81	0.85	0.81	0.85	0.92
Net Debt	-0.93	-0.93	-0.82		0.88	-0.92	-0.77	-0.65	-0.93	0.61	-0.91	-0.88	-0.53	-0.3	-0.69	-0.57	-0.72	-0.8	-0.81	-0.79	-0.8	-0.85	-0.91
Retained Earnings	-0.93	-0.92	-0.81	0.88		-0.91	-0.88	-0.66	-0.93	0.72	-0.95	-0.94	-0.71	-0.55	-0.88	-0.77	-0.88	-0.84	-0.76	-0.65	-0.76	-0.88	-0.81
Accounts Payable	0.88	0.87	0.82	-0.92	-0.91		0.74	0.62	0.87	-0.64	0.9	0.86	0.57	0.35	0.75	0.6	0.89	0.73	0.69	0.78	0.68	0.81	0.85
Short Term Investments	0.94	0.95	0.86	-0.77	-0.88	0.74		0.53	0.95	-0.64	0.93	0.92	0.6	0.81	0.71	0.62	0.75	0.87	0.89	0.55	0.89	0.92	0.78
Total Liab	0.63	0.6	0.44	-0.65	-0.66	0.62	0.53		0.63	-0.19	0.65	0.66	0.62	0.17	0.62	0.59	0.47	0.74	0.64	0.42	0.63	0.68	0.62
Total Current Assets	1.0	1.0	0.89	-0.93	-0.93	0.87	0.95	0.63		-0.65	0.98	0.96	0.59	0.6	0.74	0.61	0.77	0.89	0.9	0.7	0.9	0.94	0.89
Short Term Debt	-0.64	-0.65	-0.47	0.61	0.72	-0.64	-0.64	-0.19	-0.65		-0.65	-0.6	-0.42	-0.39	-0.6	-0.68	-0.59	-0.6	-0.53	-0.3	-0.53	-0.62	-0.48
Common Stock	0.98	0.98	0.88	-0.91	-0.95	0.9	0.93	0.65	0.98	-0.65		0.97	0.65	0.6	0.77	0.6	0.83	0.9	0.88	0.68	0.88	0.96	0.87
Net Tangible Assets	0.96	0.95	0.82	-0.88	-0.94	0.86	0.92	0.66	0.96	-0.6	0.97		0.78	0.59	0.86	0.65	0.8	0.88	0.84	0.61	0.84	0.91	0.82
Long Term Debt	0.59	0.58	0.4	-0.53	-0.71	0.57	0.6	0.62	0.59	-0.42	0.65	0.78		0.42	0.88	0.71	0.59	0.72	0.56	0.18	0.55	0.63	0.5
Net Receivables	0.6	0.62	0.68	-0.3	-0.55	0.35	0.81	0.17	0.6	-0.39	0.6	0.59	0.42		0.4	0.38	0.59	0.61	0.66	0.26	0.66	0.66	0.51
Deferred Long Term Liab	0.73	0.72	0.52	-0.69	-0.88	0.75	0.71	0.62	0.74	-0.6	0.77	0.86	0.88	0.4		0.85	0.74	0.69	0.53	0.37	0.52	0.65	0.54
Short Long Term Debt	0.61	0.6	0.37	-0.57	-0.77	0.6	0.62	0.59	0.61	-0.68	0.6	0.65	0.71	0.38	0.85		0.59	0.63	0.48	0.24	0.48	0.56	0.47
Property Plant Equipment	0.78	0.78	0.84	-0.72	-0.88	0.89	0.75	0.47	0.77	-0.59	0.83	0.8	0.59	0.59	0.74	0.59		0.65	0.59	0.7	0.58	0.74	0.76
Capital Surpluse	0.88	0.88	0.72	-0.8	-0.84	0.73	0.87	0.74	0.89	-0.6	0.9	0.88	0.72	0.61	0.69	0.63	0.65		0.94	0.44	0.94	0.97	0.82
Net Invested Capital	0.9	0.91	0.81	-0.81	-0.76	0.69	0.89	0.64	0.9	-0.53	0.88	0.84	0.56	0.66	0.53	0.48	0.59	0.94		0.56	1.0	0.96	0.88
Long Term Investments	0.72	0.71	0.85	-0.79	-0.65	0.78	0.55	0.42	0.7	-0.3	0.68	0.61	0.18	0.26	0.37	0.24	0.7	0.44	0.56		0.54	0.59	0.83
Net Working Capital	0.9	0.9	0.81	-0.8	-0.76	0.68	0.89	0.63	0.9	-0.53	0.88	0.84	0.55	0.66	0.52	0.48	0.58	0.94	1.0	0.54		0.96	0.87
Capital Stock	0.94	0.94	0.85	-0.85	-0.88	0.81	0.92	0.68	0.94	-0.62	0.96	0.91	0.63	0.66	0.65	0.56	0.74	0.97	0.96	0.59	0.96		0.89
Long Term Debt Total	0.89	0.89	0.92	-0.91	-0.81	0.85	0.78	0.62	0.89	-0.48	0.87	0.82	0.5	0.51	0.54	0.47	0.76	0.82	0.88	0.83	0.87	0.89

Click cells to compare fundamentals

Syndax Cash Per Share Historical Pattern

Today, most investors in Syndax Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Syndax Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Syndax Pharmaceuticals cash per share as a starting point in their analysis.

Syndax Pharmaceuticals Cash Per Share

Timeline

Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Competition

Predict Syndax Pharmaceuticals

Cash Per Share Over Time

Syndax Common Stock Shares Outstanding

Common Stock Shares Outstanding

38.76 Million

At this time, Syndax Pharmaceuticals' Common Stock Shares Outstanding is fairly stable compared to the past year.

In accordance with the recently published financial statements, Syndax Pharmaceuticals has a Cash Per Share of 5.82 times. This is 33.79% higher than that of the Biotechnology sector and 34.41% higher than that of the Health Care industry. The cash per share for all United States stocks is 16.17% lower than that of the firm.

Syndax Cash Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Syndax Pharmaceuticals' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Syndax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics of similar companies.

Syndax Pharmaceuticals is currently under evaluation in cash per share category among its peers.

Syndax Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Syndax Pharmaceuticals from analyzing Syndax Pharmaceuticals' financial statements. These drivers represent accounts that assess Syndax Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Syndax Pharmaceuticals' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	267.7M	918.7M	1.1B	1.5B	1.5B	1.6B
Enterprise Value	244.0M	824.0M	938.7M	1.5B	1.2B	1.3B

Syndax Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Syndax Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Syndax Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Syndax Fundamentals

	Return On Equity	-0.82
	Return On Asset	-0.49
	Operating Margin	(7.17) %
	Current Valuation	926.04 M
	Shares Outstanding	85.36 M
	Shares Owned By Insiders	0.81 %
	Shares Owned By Institutions	99.19 %
	Number Of Shares Shorted	10.66 M
	Price To Earning	126.11 X
	Price To Book	3.63 X
	Price To Sales	83.22 X
	Gross Profit	139.71 M
	EBITDA	(229.94 M)
	Net Income	(209.36 M)
	Cash And Equivalents	350.71 M
	Cash Per Share	5.82 X
	Total Debt	1.64 M
	Debt To Equity	0 %
	Current Ratio	17.19 X
	Book Value Per Share	4.28 X
	Cash Flow From Operations	(160.6 M)
	Short Ratio	14.84 X
	Earnings Per Share	(3.64) X
	Target Price	37.29
	Number Of Employees	184
	Beta	0.92
	Market Capitalization	1.33 B
	Total Asset	612.88 M
	Retained Earnings	(902.4 M)
	Working Capital	522.78 M
	Current Asset	79.72 M
	Current Liabilities	13.32 M
	Net Asset	612.88 M

About Syndax Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Syndax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC